Journal
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 15, Issue 6, Pages 629-637Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/1744666X.2019.1593141
Keywords
T cells; systemic lupus erythematosus (SLE); lupus nephritis; immune responses; interleukin (IL)-17
Categories
Funding
- Leading Initiative for Excellent Young Researchers of the Ministry of Education, Culture, Sports, Science and Technology [16810055]
Ask authors/readers for more resources
Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibodies production and immune complex deposition with systemic clinical manifestations. Interleukin (IL)-17-producing cells play a crucial role in disease pathogenesis and represent an attractive therapeutic target.Areas covered: This review provides an update on the possibility of targeting IL-17 in SLE. The rational for this approach as well as currently available and future targets are discussed.Expert opinion: Although human expression studies and animal models indicate that IL-17 blocking may be a promising therapeutic strategy for SLE, direct evidence for IL-17 inhibition in SLE patients is unavailable. Biologic therapies and small-molecule drugs that target IL-17 production are required for the achievement of a favorable clinical effect in SLE patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available